Atherosclerosis. Supplements最新文献

{"title":"Title page","authors":"","doi":"10.1016/S1567-5688(21)00014-3","DOIUrl":"https://doi.org/10.1016/S1567-5688(21)00014-3","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Page i"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1567-5688(21)00014-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138391838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project","authors":"Ulf Landmesser ,&nbsp;Angela Pirillo ,&nbsp;Michel Farnier ,&nbsp;J. Wouter Jukema ,&nbsp;Ulrich Laufs ,&nbsp;François Mach ,&nbsp;Luis Masana ,&nbsp;Terje R. Pedersen ,&nbsp;François Schiele ,&nbsp;Gabriel Steg ,&nbsp;Marco Tubaro ,&nbsp;Azfar Zaman ,&nbsp;Pepe Zamorano ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.009","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.009","url":null,"abstract":"<div><h3>Background and aims</h3><p>Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. Aim of this survey was to evaluate the compliance to ESC/EAS guidelines during the management of ACS patients and the effectiveness of secondary prevention in seven European countries.</p></div><div><h3>Methods</h3><p>By means of an online questionnaire, data on 2775 ACS patients (either acute case or follow-up patients) were collected, including data on lipid profile, medications, follow-up visit planning, screening for familial hypercholesterolemia.</p></div><div><h3>Results</h3><p>Lipid profiles were obtained for 91% of ACS patients in the acute phase, mostly within the first day of hospitalization (73%). During hospitalization, 93% of the patients received a lipid-lowering treatment; at discharge, only 66% of the patients received a high intensity statin therapy. At the first follow-up, most of the patients (77.6%) had LDL-C &gt;70 mg/dL; among them, 41% had no change in their lipid-lowering therapies. Similar data were obtained during the second follow-up visit. The analysis of a subgroup of patients with at least 2 follow-up visits and known LDL-C levels showed that the percentage of patients at goal increased from 9% to 32%, and patients with LDL-C &lt;100 mg/dL raised from 23% to 72%. Among acute cases, 44 were admitted with a diagnosis of familial hypercholesterolemia (FH); only 18% of the remaining patients were screened for FH.</p></div><div><h3>Conclusions</h3><p>Contemporary lipid management of very high CV risk patients is sub-optimal despite available treatments. Greater efforts are warranted to optimize cardiovascular prevention.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e49-e58"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"‘Diet and lifestyle’ in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members","authors":"Elke A. Trautwein ,&nbsp;Alberico L. Catapano ,&nbsp;Lale Tokgözoğlu","doi":"10.1016/j.atherosclerosissup.2021.01.003","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.003","url":null,"abstract":"<div><p>To better understand the level of knowledge and interest in ‘diet and lifestyle’ for cholesterol management and CVD prevention, European Atherosclerosis Society (EAS) members were invited to take part in an online survey. In total, 269 EAS members participated of which 64 (24%) were students/postdocs, 102 (38%) researchers involved with CVD-related research and 103 (38%) doctors and clinicians who directly interact with patients. All (99%) of the participants either agreed or strongly agreed that ‘diet and lifestyle’ have a role to play in cholesterol management, with 80% indicating that ‘diet and lifestyle’ is very or extremely important. Of the clinicians, 75% indicated that their patients voluntarily ask for ‘diet and lifestyle’ advice and over 80% said they continuously provide ‘diet and lifestyle advice’ to their patients. Of the surveyed clinicians, 91% feel sufficiently educated and confident to provide expert advice and over 90% recommend medication, diet change, frequent exercise and smoking cessation to their patients. In view of more specific dietary advice, clinicians reportedly recommend a ‘Mediterranean diet’, and advise to avoid high-fat foods, and to increase intake of high-fibre foods. Interestingly, smoking cessation and alcohol avoidance were mentioned less frequently. In view of educational needs, over half of the surveyed EAS members use the internet and ‘guidelines’ to learn about ‘diet and lifestyle’ in relation to cholesterol and CVD risk management. Clinicians tend to use ‘guidelines’ more often, while students/postdocs tend to use the internet significantly more than clinicians and CVD researchers. Regarding unmet needs for educational tools addressing specifically ‘diet and lifestyle’, clinicians feel that patient-oriented leaflets and pocket guidelines would be most beneficial materials to introduce, while students/postdocs would prefer an app. In summary, the role of ‘diet and lifestyle’ as a cornerstone of cholesterol management and CVD risk prevention seems well recognised amongst EAS members surveyed.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e9-e14"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy","authors":"Bernhard Föger ,&nbsp;Catriona Jennings ,&nbsp;Angela Pirillo ,&nbsp;Lale Tokgözoğlu ,&nbsp;Matteo Pirro ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.005","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.005","url":null,"abstract":"<div><p>The availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-moderate hypercholesterolemia, which are not eligible for a pharmacological approach and are not far from the cholesterol target recommended for their risk category, functional foods or nutraceuticals may be considered as supplement to reduce their CV risk status. Of note, counseling and lifestyle intervention in people at moderate CV risk represents a major issue for both preventing a further risk increase and reducing the need for drugs. Studies on general populations have clearly indicated that lifestyle interventions translate into a clinical benefit, with reduction of the incidence of myocardial infarction and the risk of developing type 2 diabetes.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e25-e29"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool","authors":"Alessandro Sionis ,&nbsp;Alberico L. Catapano ,&nbsp;Gaetano M. De Ferrari ,&nbsp;Dariusz Dudek ,&nbsp;J. Wouter Jukema ,&nbsp;Ulf Landmesser ,&nbsp;Angela Pirillo ,&nbsp;François Schiele ,&nbsp;Azfar Zaman ,&nbsp;Jose L. Zamorano","doi":"10.1016/j.atherosclerosissup.2021.01.011","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.011","url":null,"abstract":"<div><p>Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients.</p><p>Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS guidelines. This tool is built in 3 sections. The first is a questionnaire to assess the lipid management practice from the acute phase up to 12 months of follow-up. The main topics covered in this section relate to 1) acute phase (lipid management of ACS patients during hospitalization; 2) discharge (lipid management at discharge, with focus on follow-up plan); 3) follow-up (lipid management at the time of first and subsequent follow-ups); 4) referral pathway for definitive lipid management care of post-ACS patients; 5) evaluation of the achieved goal at 6 months to 1 year and key implications. The second section is a brief report to position the results against other European Union clinical practice and European guidelines. The last section allows the physician to evaluate and consider the implementation of one or more strategies, successfully developed in leading European centers, in order to optimize their own clinical practice.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e65-e71"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study","authors":"Jacek J. Jóźwiak ,&nbsp;Krzysztof Studziński ,&nbsp;Tomasz Tomasik ,&nbsp;Adam Windak ,&nbsp;Mirosław Mastej ,&nbsp;Alberico L. Catapano ,&nbsp;Kausik K. Ray ,&nbsp;Dimitri P. Mikhailidis ,&nbsp;Peter P. Toth ,&nbsp;George Howard ,&nbsp;Gregory Y.H. Lip ,&nbsp;Maciej Tomaszewski ,&nbsp;Fadi J. Charchar ,&nbsp;Naveed Sattar ,&nbsp;Bryan Williams ,&nbsp;Thomas M. MacDonald ,&nbsp;Dariusz Nowak ,&nbsp;Łukasz Skowron ,&nbsp;Sławomir Kasperczyk ,&nbsp;Maciej Banach","doi":"10.1016/j.atherosclerosissup.2021.01.004","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.004","url":null,"abstract":"<div><h3>Background and aim</h3><p>To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients.</p></div><div><h3>Methods</h3><p>A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices.</p></div><div><h3>Results</h3><p>Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60% of the recruited patients had hypertension (HTN), &gt;80% had dyslipidaemia and &lt;15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist circumference exceed norm for the European population. Less than half of the patients were current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure and glucose levels but lower low density lipoprotein-cholesterol level.</p></div><div><h3>Conclusions</h3><p>The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e15-e24"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients","authors":"Gerald F. Watts ,&nbsp;Alberico L. Catapano ,&nbsp;Luis Masana ,&nbsp;Alberto Zambon ,&nbsp;Angela Pirillo ,&nbsp;Lale Tokgözoğlu","doi":"10.1016/j.atherosclerosissup.2021.01.006","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.006","url":null,"abstract":"<div><p>The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of &lt;55 mg/dL or even &lt;40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e30-e34"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies","authors":"Asiiat S. Alieva ,&nbsp;Elena Olmastroni ,&nbsp;Olga V. Reutova ,&nbsp;Oxana P. Rotar ,&nbsp;Alexandra O. Konradi ,&nbsp;Evgeny V. Shlyakhto ,&nbsp;Andrea Baragetti ,&nbsp;Liliana Grigore ,&nbsp;Fabio Pellegatta ,&nbsp;Manuela Casula ,&nbsp;Elena Tragni ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.008","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.008","url":null,"abstract":"<div><h3>Background and aim</h3><p>The metabolic syndrome (MetS) has become one of the most important clinical issues in the cardiovascular field for this decade because of the marked increase in cardiovascular (CV) risk associated with a clustering of risk factors. The aim of the current study was to evaluate the relationship between MetS and its components and cardiovascular disease (CVD).</p></div><div><h3>Methods</h3><p>This population-based cross-sectional study was based on data from two studies carried out in Russia (ESSE-RF) and Italy (PLIC). One sample from each cohort was selected, matching individuals by sex and age. A comparison between samples of MetS components distribution and CV risk, according to SCORE chart, has been conducted.</p></div><div><h3>Results</h3><p>A total of 609 individuals (mean [SD] age 55 [8] years, about 39% males) for each cohort were selected. Almost half of PLIC cohort participants belonged to the moderate CV risk group (47% vs 27%), while in ESSE-RF cohort a relatively higher prevalence of individuals classified in the high and very high risk group was observed (19% vs 11%, 21% vs 6%, respectively). Overall, 43% of ESSE-RF participants were diagnosed with MetS, compared with the 27% of PLIC members (the difference in prevalence becomes 37% vs 21%, considering a more conservative cut-off for waist circumference). Both cohorts showed a trend towards the increase of MetS components moving from the lowest to the highest CV risk class, with a high prevalence of patients with four or five MetS determinants allocated in the high/very high CV risk group.</p></div><div><h3>Conclusions</h3><p>Developing effective public health strategies for the prevention, detection and treatment of MetS should be an urgent priority to reduce the burden of CVD, not only in subjects at high/very high CV risk, but also in those characterized by a lower risk, as even rare CV events that come from low risk group bring a tangible burden to healthcare systems.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e41-e48"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid Clinics Network. Rationale and design of the EAS global project","authors":"Asiiat S. Alieva ,&nbsp;Lale Tokgözoğlu ,&nbsp;Kausik K. Ray ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.002","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.002","url":null,"abstract":"<div><p>The evidence of the causal role of low-density lipoprotein cholesterol in the development of atherosclerotic cardiovascular disease is well-established. The clearly identified common position of the European guidelines proclaims necessity to decrease LDL-C concentrations based on a proper risk stratification. However, current worldwide situation with the lipid management still demonstrates inadequate dyslipidemia control, that is probably related to a healthcare system issues. As the need to standardize and implement approaches following the guidelines into clinical practice remains a challenge, the EAS initiates the <em>Lipid Clinics Network</em> project, aiming to provide a structure to establish uniform EU-wide standards of diagnosis, management and treatment of patients with lipid disorders, based on the ESC/EAS Guidelines on management of dyslipidaemias.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"42 ","pages":"Pages e6-e8"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study.","authors":"J. Jozwiak, Krzysztof Studziński, T. Tomasik, A. Windak, M. Mastej, A. Catapano, K. Ray, D. Mikhailidis, P. Toth, G. Howard, G. Lip, M. Tomaszewski, F. Charchar, N. Sattar, B. Williams, T. MacDonald, D. Nowak, Ł. Skowron, S. Kasperczyk, M. Banach","doi":"10.1093/ehjci/ehaa946.2847","DOIUrl":"https://doi.org/10.1093/ehjci/ehaa946.2847","url":null,"abstract":"BACKGROUND AND AIM\u0000To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients.\u0000\u0000\u0000METHODS\u0000A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices.\u0000\u0000\u0000RESULTS\u0000Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60% of the recruited patients had hypertension (HTN), >80% had dyslipidaemia and <15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist circumference exceed norm for the European population. Less than half of the patients were current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure and glucose levels but lower low density lipoprotein-cholesterol level.\u0000\u0000\u0000CONCLUSIONS\u0000The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"3 1","pages":"e15-e24"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84557244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}